Targets › CYP11B2
4 programs from 3 companies in 8 trials: 5 Phase 3, 2 Phase 2, 1 Phase 1; Cardiovascular, Metabolic and endocrine, Genitourinary; next expected readout Dec 2026.
A cytochrome P450 monooxygenase that catalyzes the biosynthesis of aldosterone, the main mineralocorticoid in the human body responsible for salt and water homeostasis, thus involved in blood pressure regulation, arterial hypertension, and the development of heart failure. Catalyzes three sequential oxidative reactions of 11-deoxycorticosterone (21-hydroxyprogesterone), namely 11-beta hydroxylation, followed by two…. (UniProt, P19099)
Open in Phaseline: the race on CYP11B2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AstraZeneca | baxdrostat Aldosterone synthase inhibitor | CYP11B2 | Phase 3 | Primary Hyperaldosteronism; Uncontrolled Hypertension; Chronic Kidney Disease and Hypertension | Dec 2026 |
| Mineralys Therapeutics | lorundrostat Aldosterone synthase inhibitor | CYP11B2 | Phase 3 | Hypertension | May 2027 |
| University Medical Center Groningen | vicadrostat Aldosterone synthase inhibitor | CYP11B2 | Phase 2 | CKD | Feb 2028 |
| University Medical Center Groningen | [18F]CETO tracer PET tracer with high specificity for steroidogenic enzymes CYP11B1 and CYP11B2 in adrenal | CYP11B1, CYP11B2 | Phase 1 | Primary Aldosteronism | May 2027 |
Chronic Kidney Disease and Hypertension (3) Primary Aldosteronism (1) Primary Hyperaldosteronism (1) Uncontrolled Hypertension (1) Hypertension (1) CKD (1)
small molecule (4)
University Medical Center Groningen (2) AstraZeneca (1) Mineralys Therapeutics (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.